Quantum-Si Announces $50M Registered Direct Offering of Common Stock
PorAinvest
lunes, 7 de julio de 2025, 5:17 pm ET1 min de lectura
MORN--
The proceeds from the offering will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering, which is being made pursuant to an effective shelf registration statement on Form S-3 [1].
This announcement follows the company's mission to transform proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The platform enables real-time kinetic-based detection, allowing researchers to access dynamic, functional protein insights with unparalleled resolution [1].
Quantum-Si's forward-looking statements include expectations regarding future performance, data and product launches, and investor confidence. However, the company cautions that actual results may differ from these expectations due to various risks and uncertainties, including regulatory changes, competition, and market conditions [1].
Investors interested in more information can contact Jeff Keyes, Chief Financial Officer, at ir@quantum-si.com, or Katherine Atkinson, SVP, Commercial Marketing, at media@quantum-si.com.
References:
[1] https://www.morningstar.com/news/business-wire/20250703705354/quantum-si-incorporated-announces-pricing-of-50-million-registered-direct-offering-of-common-stock
QSI--
Quantum-Si Incorporated has announced the pricing of a $50 million registered direct offering of common stock. The offering involves the sale of 29,940,119 shares at $1.67 per share to a single institutional investor. The closing of the offering is expected on July 8, 2025. The proceeds will be used for working capital and general corporate purposes.
Quantum-Si Incorporated (Nasdaq: QSI), a proteomics technology company, has announced the pricing of a $50 million registered direct offering of common stock. The offering involves the sale of 29,940,119 shares at $1.67 per share to a single institutional investor. The closing of the offering is expected on July 8, 2025, subject to customary closing conditions [1].The proceeds from the offering will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering, which is being made pursuant to an effective shelf registration statement on Form S-3 [1].
This announcement follows the company's mission to transform proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The platform enables real-time kinetic-based detection, allowing researchers to access dynamic, functional protein insights with unparalleled resolution [1].
Quantum-Si's forward-looking statements include expectations regarding future performance, data and product launches, and investor confidence. However, the company cautions that actual results may differ from these expectations due to various risks and uncertainties, including regulatory changes, competition, and market conditions [1].
Investors interested in more information can contact Jeff Keyes, Chief Financial Officer, at ir@quantum-si.com, or Katherine Atkinson, SVP, Commercial Marketing, at media@quantum-si.com.
References:
[1] https://www.morningstar.com/news/business-wire/20250703705354/quantum-si-incorporated-announces-pricing-of-50-million-registered-direct-offering-of-common-stock
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios